Application and Prospects of Butylphthalide for the Treatment of Neurologic Diseases
Introduction
3-N-butylphthalide (NBP), a compound derived from celery oil, has emerged as a multi-target neuroprotective agent with broad therapeutic potential in neurologic and non-neurologic diseases. Its chemical structure (C₁₂H₁₄O₂) allows it to cross the blood-brain barrier, reaching peak plasma concentrations within 1.25 hours and exhibiting a prolonged half-life of 11.84 hours. NBP’s primary mechanisms include reconstructing microcirculation, protecting mitochondrial function, inhibiting oxidative stress, suppressing apoptosis, and modulating inflammatory responses. These properties underpin its clinical applications, particularly in ischemic stroke, while growing evidence supports its efficacy in neurodegenerative disorders, cerebral edema, epilepsy, and systemic conditions like diabetes and atherosclerosis.
Pharmacological Mechanisms of NBP
1. Microcirculation Reconstruction
NBP enhances cerebral blood flow by targeting multiple pathways. It inhibits arachidonic acid (AA) metabolism, reducing pro-inflammatory leukotriene B4 and thromboxane A2 (TXA2) levels while increasing vasodilators like nitric oxide (NO) and prostaglandin I₂ (PGI₂). In rat models of cerebral ischemia-reperfusion, NBP elevated the PGI₂/TXA₂ ratio, promoting vasodilation and perfusion. Additionally, NBP suppresses platelet aggregation by inhibiting cytosolic phospholipase A₂ (cPLA₂) phosphorylation and calcium mobilization, thereby reducing thrombus formation. It also upregulates vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1α (HIF-1α), stimulating angiogenesis and capillary density in ischemic regions.
2. Mitochondrial Protection
NBP preserves mitochondrial integrity by enhancing Na⁺/K⁺-ATPase and Ca²⁺-ATPase activity, maintaining membrane potential and electrolyte balance. In oxygen-glucose deprivation (OGD) models, NBP reduced reactive oxygen species (ROS) accumulation, prevented mitochondrial membrane depolarization, and restored cytochrome c oxidase activity. It also inhibits cytochrome c release, a key step in apoptosis, and upregulates antioxidant enzymes like superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px). Derivatives like (S)-ZJM-289 further mitigate neuronal damage by stabilizing mitochondrial respiration and reducing calcium overload.
3. Anti-Inflammatory and Anti-Apoptotic Effects
NBP modulates inflammatory pathways by downregulating Toll-like receptor 4 (TLR4)/nuclear factor-κB (NF-κB) signaling and suppressing pro-inflammatory cytokines (e.g., TNF-α, IL-1β). In Alzheimer’s disease (AD) models, NBP inhibited NLRP3 inflammasome activation via the Nrf2-TXNIP-TrX axis, reducing neuroinflammation. Apoptosis is attenuated through caspase-3/9 inhibition, Bcl-2 upregulation, and Bax downregulation. NBP also enhances heat shock protein 70 (HSP70) expression, protecting neurons from ischemic injury.
Clinical and Preclinical Applications in Neurologic Diseases
1. Ischemic Stroke
NBP is approved in China for ischemic stroke treatment, demonstrating 74.7% efficacy in clinical trials. It reduces infarct size, improves cerebral blood flow, and preserves the blood-brain barrier (BBB) by inhibiting matrix metalloproteinase-9 (MMP-9) and enhancing tight junction proteins. In rat models, NBP increased ATP synthesis, normalized glutamate/aspartate levels, and activated the PI3K/Akt pathway, promoting neuronal survival.
2. Alzheimer’s Disease (AD)
NBP mitigates synaptic dysfunction and amyloid-β toxicity. In APP/PS1 transgenic mice, NBP reduced soluble Aβ oligomers, tau hyperphosphorylation (Ser199, Thr205), and oxidative stress. It upregulated synaptic proteins (synaptophysin, PSD-95) and BDNF/TrkB signaling, enhancing neurogenesis and cognitive function. NBP also reversed Aβ-induced mitochondrial dysfunction by restoring Bcl-2 expression and inhibiting caspase activation.
3. Vascular Dementia (VaD)
NBP improves cognitive deficits in hypoperfusion models by enhancing VEGF and basic fibroblast growth factor (bFGF) expression, promoting angiogenesis. It restores SOD activity, reduces malondialdehyde (MDA) levels, and activates the Akt pathway, protecting hippocampal neurons from ischemic damage.
4. Parkinson’s Disease (PD)
In rotenone-induced PD models, NBP increased tyrosine hydroxylase (TH)-positive neurons in the substantia nigra, reduced oxidative stress (↑GSH, ↓MDA), and activated autophagy to degrade α-synuclein aggregates. These effects correlate with improved motor function and dopamine synthesis.
5. Cerebral Edema and Traumatic CNS Injury
NBP attenuates post-traumatic brain edema by upregulating VEGF and endothelial nitric oxide synthase (eNOS), restoring BBB integrity. In spinal cord injury models, NBP inhibited endoplasmic reticulum stress (↓CHOP, ↓ATF6) and preserved blood-spinal cord barrier function, reducing inflammation and apoptosis.
6. Carbon Monoxide (CO) Poisoning
NBP ameliorates CO-induced cognitive dysfunction by inhibiting calpain-1/CaMKII signaling, preserving hippocampal ultrastructure, and upregulating Bcl-2. Combined with hyperbaric oxygen, NBP significantly improved Mini-Mental State Examination (MMSE) scores in patients.
7. Epilepsy
NBP reduces seizure severity by modulating calcium-permeable AMPA receptors (CP-AMPARs) and restoring glutamate/GABA balance. In pilocarpine-induced epilepsy, NBP reversed neuronal loss in the hippocampus, upregulated GAD65/67 (GABA synthesis), and enhanced BDNF/Klotho expression, alleviating anxiety and depression.
8. Autoimmune Diseases and ALS
NBP suppressed phosphoglycerate mutase 5 (PGAM5)-mediated necroptosis in autoimmune encephalomyelitis and improved mitochondrial function in experimental myositis. In amyotrophic lateral sclerosis (ALS) models, NBP delayed motor neuron degeneration by inhibiting TNF-α/NF-κB and enhancing Nrf2/heme oxygenase-1 (HO-1) pathways.
Applications in Non-Neurologic Diseases
1. Diabetes and Diabetic Complications
NBP reduced hyperglycemia and oxidative stress in diabetic rats, enhancing VEGF expression and inhibiting caspase-3 in retinal cells. It delayed diabetic cataract formation by lowering ROS and MDA levels.
2. Atherosclerosis
NBP attenuated plaque formation by downregulating vascular cell adhesion molecule-1 (VCAM-1) and reducing lipid peroxidation. It also improved cardiac function post-myocardial infarction via PI3K/Akt/Nrf2 signaling, inhibiting ventricular remodeling and arrhythmias.
Conclusion
NBP’s multi-target mechanisms—spanning microcirculation restoration, mitochondrial protection, anti-inflammatory, and anti-apoptotic effects—position it as a versatile therapeutic agent. While its role in ischemic stroke is well-established, emerging evidence highlights potential in neurodegenerative diseases, epilepsy, and systemic conditions. Further research is needed to elucidate unexplored pathways, optimize dosing, and validate long-term safety.
doi.org/10.1097/CM9.0000000000000289
Was this helpful?
0 / 0